The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Top AML highlights from ASH 2024: what community oncologists should know
In this video, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares her top highlights in acute myeloid leukemia (AML) from ASH 2024, focusing on the excitement around menin inhibitors. Dr Wang comments on the recent approval of revumenib and the promising results from combination studies with other agents. Dr Wang also highlights novel emerging menin inhibitors, including enzomenib and bleximenib, and summarizes other exciting abstracts presented at the meeting. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
